Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Schizophrenia

  Free Subscription


Articles published in J Clin Psychopharmacol

Retrieve available abstracts of 81 articles:
HTML format
Text format



Single Articles


    April 2017
  1. KIM DD, Lang DJ, Warburton DE, Barr AM, et al
    Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia.
    J Clin Psychopharmacol. 2017;37:273-274.
    PubMed     Text format    



  2. Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia: Erratum.
    J Clin Psychopharmacol. 2017;37:168.
    PubMed     Text format    


    March 2017
  3. GAHR M, Hiemke C, Connemann BJ, Schonfeldt-Lecuona C, et al
    First-Episode Psychosis Possibly due to Roxithromycin-Related Inhibition of Metabolization of Tetrahydrocannabinol.
    J Clin Psychopharmacol. 2017 Mar 21. doi: 10.1097/JCP.0000000000000707.
    PubMed     Text format    


  4. LIN CH, Lane HY
    Clotiapine Monotherapy in a Patient With Clozapine-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2017 Mar 21. doi: 10.1097/JCP.0000000000000692.
    PubMed     Text format    


  5. YOSHIMURA Y, Takeda T, Kishi Y, Harada T, et al
    Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
    J Clin Psychopharmacol. 2017 Mar 17. doi: 10.1097/JCP.0000000000000689.
    PubMed     Text format     Abstract available


  6. CHEN TR, Chen YC, Ouyang WC
    Zotepine-Associated Hypothermia in a Schizophrenic Inpatient.
    J Clin Psychopharmacol. 2017 Mar 9. doi: 10.1097/JCP.0000000000000686.
    PubMed     Text format    


    February 2017
  7. GLICK ID, Davis JM, Zamora D, Ballon J, et al
    Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?: A Naturalistic, Long-Term Follow-Up Study.
    J Clin Psychopharmacol. 2017 Feb 13. doi: 10.1097/JCP.0000000000000680.
    PubMed     Text format     Abstract available


  8. CHEN SF, Shen YC
    5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia.
    J Clin Psychopharmacol. 2017;37:114-118.
    PubMed     Text format    


  9. CHANG WH, Chen KC, Lee IH, Chi MH, et al
    Unaltered Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia After 6 Months of Antipsychotics Treatment: A Naturalistic Study.
    J Clin Psychopharmacol. 2017;37:21-26.
    PubMed     Text format     Abstract available


    January 2017
  10. CITROME L
    Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm.
    J Clin Psychopharmacol. 2017 Jan 30. doi: 10.1097/JCP.0000000000000665.
    PubMed     Text format     Abstract available


  11. MOROZOVA M, Burminskiy D, Rupchev G, Lepilkina T, et al
    5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial).
    J Clin Psychopharmacol. 2017 Jan 30. doi: 10.1097/JCP.0000000000000673.
    PubMed     Text format     Abstract available


    December 2016
  12. CHAN HY, Pan YJ, Chen JJ, Chen CH, et al
    Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia: A Naturalistic, Comparative Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  13. LI Q, Chen D, Liu T, Walss-Bass C, et al
    Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia.
    J Clin Psychopharmacol. 2016;36:643-648.
    PubMed     Text format     Abstract available


  14. ENGLISCH S, Jung HS, Lewien A, Becker A, et al
    Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    J Clin Psychopharmacol. 2016;36:597-607.
    PubMed     Text format     Abstract available


    October 2016
  15. ENGLISCH S, Jung HS, Lewien A, Becker A, et al
    Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  16. ZHENG W, Zheng YJ, Li XB, Tang YL, et al
    Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  17. MAN SC, Li XB, Wang HH, Yuan HN, et al
    Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Controlled Trial.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  18. GAO K, Fang F, Wang Z, Calabrese JR, et al
    Subjective Versus Objective Weight Gain During Acute Treatment With Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  19. FJUKSTAD KK, Engum A, Lydersen S, Dieset I, et al
    Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  20. CHEN WY, Lin SK
    Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2016;36:492-5.
    PubMed     Text format     Abstract available


    September 2016
  21. EDLINGER M, Rettenbacher MA, Kemmler G, Biedermann F, et al
    Prescribing Practice in Inpatients Versus Outpatients With Schizophrenia Initiating Treatment With Second-Generation Antipsychotics: A Naturalistic Follow-Up Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  22. BOERMAN R, Cohen D, Schulte PF, Nugter A, et al
    Prevalence of Vitamin D Deficiency in Adult Outpatients With Bipolar Disorder or Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  23. GONZALEZ-RODRIGUEZ A, Catalan R, Penades R, Ruiz Cortes V, et al
    Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  24. THAMIZH JS, Menon V, Selvakumar N, Rajkumar RP, et al
    Treatment-Emergent Psychosis With Disulfiram in a Patient With Late-Onset Alcohol Use Disorder and No Contributory Factors.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  25. HIRAKAWA H, Terao T, Tanaka T, Sato H, et al
    A Case of Mutism in Noncatatonic Schizophrenia Responding to Small Dose of Fluvoxamine Addition to Clozapine.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


    July 2016
  26. MISIAK B, Frydecka D, Beszlej JA, Samochowiec A, et al
    Effects of Antipsychotic Treatment on Depressive Symptoms With Respect to Genetic Polymorphisms Related to Dopaminergic and Serotoninergic Neurotransmission in Schizophrenia Patients.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


    June 2016
  27. GARCIA S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, et al
    Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  28. SUZUKI H, Hibino H, Inoue Y, Takaya A, et al
    Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  29. FIGUEIREDO T, Segenreich D, Mattos P
    Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  30. ANIL YAGCIOGLU AE, Yoca G, Ayhan Y, Karaca RO, et al
    Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine.
    J Clin Psychopharmacol. 2016;36:257-61.
    PubMed     Text format     Abstract available


  31. LANGLEY-DEGROOT M, Joshi Y, Lehman D, Rao S, et al
    Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report.
    J Clin Psychopharmacol. 2016;36:277-9.
    PubMed     Text format    


  32. BARAK N, Beck Y, Albeck JH
    A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.
    J Clin Psychopharmacol. 2016;36:253-6.
    PubMed     Text format     Abstract available


  33. KREININ A, Miodownik C, Mirkin V, Gaiduk Y, et al
    Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine.
    J Clin Psychopharmacol. 2016;36:200-5.
    PubMed     Text format     Abstract available


  34. STRUYE A, Depuydt C, Abdel Sater E, Dubois V, et al
    Toxic Epidermal Necrolysis Related to Paliperidone Palmitate: First Case Report.
    J Clin Psychopharmacol. 2016;36:279-82.
    PubMed     Text format    


    May 2016
  35. OH N, See YM, Remington G, Lee J, et al
    Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


    April 2016
  36. ROSSO G, Pessina E, Martini A, Di Salvo G, et al
    Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia: A 12-Month Observational Prospective Cohort Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  37. SCHWARTZ DL
    Quercetin as an Augmentation Agent in Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  38. SCANGOS KW, Caton M, Newman WJ
    Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  39. LLOYD H, Deng C
    Interaction of Dopamine D2 and 5-HT1A Receptor Partial Agonism on Antipsychotic Efficacy.
    J Clin Psychopharmacol. 2016;36:192-3.
    PubMed     Text format    


  40. GONZALEZ-PABLOS E, Valles-de la Calle JM, Iglesias-Santa Polonia F, Camara Barrio S, et al
    A Case Report of Camptocormia Coinciding With Olanzapine Use.
    J Clin Psychopharmacol. 2016;36:183-4.
    PubMed     Text format    


  41. TOURNIKIOTI K, Douzenis A, Antoniadou A, Papazahos K, et al
    Eosinophilia Associated With Olanzapine.
    J Clin Psychopharmacol. 2016;36:180-1.
    PubMed     Text format    


  42. LAU SL, Muir C, Assur Y, Beach R, et al
    Predicting Weight Gain in Patients Treated With Clozapine: The Role of Sex, Body Mass Index, and Smoking.
    J Clin Psychopharmacol. 2016;36:120-4.
    PubMed     Text format     Abstract available


  43. SILVA MA, Key S, Han E, Malloy MJ, et al
    Acute Pancreatitis Associated With Antipsychotic Medication: Evaluation of Clinical Features, Treatment, and Polypharmacy in a Series of Cases.
    J Clin Psychopharmacol. 2016;36:169-72.
    PubMed     Text format     Abstract available


  44. USTOHAL L, Mayerova M, Valkova B, Sedlakova H, et al
    Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment.
    J Clin Psychopharmacol. 2016;36:181-3.
    PubMed     Text format    


  45. LEUNG JG, Nelson S, Barreto JN, Schiavo DN, et al
    Necrotizing Pneumonia in the Setting of Elevated Clozapine Levels.
    J Clin Psychopharmacol. 2016;36:176-8.
    PubMed     Text format    


  46. GURRERA RJ, Parlee AC, Perry NL
    Aspiration Pneumonia: An Underappreciated Risk of Clozapine Treatment.
    J Clin Psychopharmacol. 2016;36:174-6.
    PubMed     Text format    


    February 2016
  47. SCHULTE PF, Bocxe JT, Doodeman HJ, van Haelst IM, et al
    Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  48. BOGERS JP, Schulte PF, Van Dijk D, Bakker B, et al
    Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved?
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  49. NASSER AF, Henderson DC, Fava M, Fudala PJ, et al
    Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  50. COMACCHIO C, Dusi N, Lasalvia A
    Successful Use of Single Doses of Granulocyte-Colony Stimulating Factor (G-CSF) in the Treatment of Late-Onset Agranulocytosis Associated With Clozapine in a Patient With Treatment-Resistant Schizophrenia: A Case Report.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  51. BO QJ, Li XB, Wang ZM, Li AN, et al
    Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available



  52. Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Satiety Signaling in Overweight People With Schizophrenia: Erratum.
    J Clin Psychopharmacol. 2016;36:26.
    PubMed     Text format    


  53. YOSHIMURA B, Kishi Y
    Hospitalization Risk Before and After Discontinuation of Long-Acting Injectable Antipsychotics.
    J Clin Psychopharmacol. 2016;36:86-7.
    PubMed     Text format    


    December 2015
  54. FERNANDEZ-MIRANDA JJ, Carames-Garcia V, Sanchez-Garcia A
    Effectiveness, Good Tolerability, and High Compliance of Doses of Risperidone Long-Acting Injectable Higher Than 75 mg in People With Severe Schizophrenia: A 3-Year Follow-Up.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  55. SENDA M, Bessho K, Oshima E, Sakamoto S, et al
    Anti-Inflammatory Therapy and Immunotherapy Were Partially Effective in a Patient With Anti-N-Methyl-D-Aspartate Receptor Antibodies and a Special Subgroup of Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


  56. SHOJA SHAFTI S, Akbari S
    Intractability of Deficit Syndrome of Schizophrenia Against Adjunctive Modafinil.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  57. HWANG TJ, Lo WM, Chan HY, Lin CF, et al
    Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  58. GARDNER DM, Abidi S, Ursuliak Z, Morrison J, et al
    Incidence of Oculogyric Crisis and Long-Term Outcomes With Second-Generation Antipsychotics in a First-Episode Psychosis Program.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  59. CRESSMAN AM, Macdonald EM, Huang A, Gomes T, et al
    Prescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  60. TAKEUCHI H, Fervaha G, Remington G
    Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


  61. JHA MK, Lambert ES, Beadles BA, Spradling B, et al
    A Case of Frontotemporal Dementia Presenting With Treatment-Refractory Psychosis and Extreme Violence: Response to Combination of Clozapine, Medroxyprogesterone, and Sertraline.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


    August 2015
  62. LIANG Y, Su YA, Zhao ZG, Gao N, et al
    Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  63. SIMSEK S, Gencoglan S, Yuksel T, Kaplan I, et al
    Lower Brain-Derived Neurotropic Factor Levels in Untreated Adolescents With First-Episode Psychosis.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  64. CHEN PY, Lu ML, Huang MC, Kao CF, et al
    The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients With Schizophrenia.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  65. BUMB JM, Solojenkina X, Zink M
    Schizophreniform Psychosis During Treatment With Alitretinoin.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


    June 2015
  66. KELLY DL, Sullivan KM, McEvoy JP, McMahon RP, et al
    Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  67. KANE JM, Zukin S, Wang Y, Lu K, et al
    Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  68. DOSHI JA, Pettit AR, Stoddard JJ, Zummo J, et al
    Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


  69. WARTELSTEINER F, Hofer A
    Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs: A Case Report.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


  70. MAHGOUB N
    Does Combining Aripiprazole With Other Antipsychotics Worsen Psychosis?
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


    April 2015
  71. MBSC EN, Joshua N, Morgan C, Rossell SL, et al
    The effect of ketamine on configural facial processing.
    J Clin Psychopharmacol. 2015;35:188-91.
    PubMed     Text format     Abstract available


  72. GONZALEZ-RODRIGUEZ A, Molina-Andreu O, Penades R, Bernardo M, et al
    Therapeutic approach to delusional disorder based on psychopathological complexity: proposal for a decision model.
    J Clin Psychopharmacol. 2015;35:201-2.
    PubMed     Text format    


  73. KANG SG, Na KS, Lee HJ, Chee IS, et al
    DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
    J Clin Psychopharmacol. 2015;35:158-62.
    PubMed     Text format     Abstract available


  74. CALIGIURI MP, Teulings HL, Dean CE, Lohr JB, et al
    A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia.
    J Clin Psychopharmacol. 2015;35:168-74.
    PubMed     Text format     Abstract available


    February 2015
  75. TAKAHASHI T, Masuya Y, Ueno K, Watanabe K, et al
    Clozapine-Related Negative Myoclonus Associated With Urinary Tract Infection: A Case Report.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


  76. ZAI CC, Tiwari AK, Chowdhury NI, Brandl EJ, et al
    Association study of GABAA alpha2 receptor subunit gene variants in antipsychotic-associated weight gain.
    J Clin Psychopharmacol. 2015;35:7-12.
    PubMed     Text format     Abstract available


  77. HASHIMOTO N, Maeda T, Okubo R, Narita H, et al
    Simple pulmonary eosinophilia associated with clozapine treatment.
    J Clin Psychopharmacol. 2015;35:99-101.
    PubMed     Text format    


  78. CASTELNOVO A, Zambrelli E, Canevini MP, Cavallotti S, et al
    Occipital seizures and visual pseudohallucinations associated with the addition of bupropion to clozapine: a case report.
    J Clin Psychopharmacol. 2015;35:97-9.
    PubMed     Text format    


  79. HELLAND A, Syrstad VE, Spigset O
    Prolonged elimination of paliperidone after administration of paliperidone palmitate depot injections.
    J Clin Psychopharmacol. 2015;35:95-6.
    PubMed     Text format    


    August 2014
  80. LAKO IM, Liemburg EJ, Van den Heuvel ER, Knegtering H, et al
    Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis: a reply.
    J Clin Psychopharmacol. 2014;34:532-3.
    PubMed     Text format    


  81. LEE J, Takeuchi H, Remington G
    Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls.
    J Clin Psychopharmacol. 2014;34:530-2.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: